Volume 41, Number 9, September 1996

 
   
623
John D. Paulson, M.D.
The early results appear encouraging, and as larger numbers are obtained, this protocol could greatly reduce the risk to urinary structures.
 
 


629
John A. Worrell, M.D., Jeanne A. Cullinan, M.D., Cynthia C. Youree, M.D., Frank E. Carroll, M.D., and Christine H. Lorenz, Ph.D.
Wider appreciation of the physiologic information available on the plain chest radiograph may prove invaluable in treating pulmonary edema in pregnancy.
 
 


633
John C. Arpels, M.D.
Whenever brain estrogen levels fall below the minimum brain estrogen requirement, brain center dysfunction may ensue.
 
 


640
Frederick Friedman, Jr., M.D., Alan B. Copperman, M.D., Michael L. Brodman, M.D., Dipti Shah, M.D., Benjamin Sandler, M.D., and Lawrence Grunfeld, M.D.
Our data support the generally favorable outcome seen in pregnancies conceived through ovum donation.
 
 


645
Karen E. Elkind-Hirsch, Ph.D., Carol Anania, M.D., and Russell Malinak, M.D.
Oral contraceptive therapy after gonadotropin-releasing hormone agonist administration is effective in maintaining ovarian androgen suppression in most women with polycystic ovary disease.
 
 


653
Authors: Giuseppe Del Priore, M.D., M.P.H., Pamela R. Gilmore, M.D., Terry Maag, M.D., David P. Warshal, M.D., and Teresa H. Cheon, M.D.
Colposcopically directed cervical punch biopsy results are equally poor predictors of cone biopsy results in human immunodeficiency virus-positive and -negative women.
 
 


658
Beverley Vollenhoven, M.D., Ph.D., Minna Selub, M.D., Oscar Davidson, M.D., Holly Lefkow, R.N., Margaret Henault, Ph.D., Nurys Serpa, B.S., M.S., and Terry T. Hung, M.D., Ph.D.
Human menopausal gonadotropin in association with one intrauterine insemination after human chorionic gonadotropin administration appears valid.
 
 


665
Italian Study Group on Vulvar Disease
In a study of 370 cases of vulvar intraepithelial neoplasia, the lesions proved to be extremely heterogeneous.
 
 


671
Renee R. Eger, M.D., and Jeffrey F. Peipert, M.D., M.P.H.
The fact that women with high grade lesions respond differently than women with low grade lesions points to potential educational interventions that might increase compliance rates.
 
 


675
William J. Meyer, M.D., Jodi Carbone, M.D., Daniel W. Gauthier, M.D., and Deborah A. Gottmann, M.D.
Glucose screening early in gestation, at 12-24 weeks, in patients older than 30, who are black or who have risk factors, may be useful in the early detection of gestational diabetes.
 
 


680
Zeev Weiner, M.D., George Farmakides, M.D., Helen Hsieh, M.D., and Dev Maulik, M.D., Ph.D.
External cephalic version appears to be safe for the mother and fetus, although computerized fetal heart rate analysis showed changes that may persist for several minutes.
 
 


685
Michele R. Lauria, M.D., Mitchell P. Dombrowski, M.D., Virginia Delaney-Black, M.D., and Sidney F. Bottoms, M.D.
Gestational age is a significant predictor of neonatal mortality, morbidity and hospital course, statistically independent of biochemical lung maturity.
 
 


692
Joyce M. Piper, Dr.P.H.,# M. Wendy Atkinson, M.D., Edward F. Mitchel, Jr., M.S., Suzanne P. Cliver, B.A., Mary Snowden, B.S.N., and Shan C. Wilson, R.N.
The use of combined corticosteroids with tocolytics was associated with better neonatal outcomes than the use of corticosteroids alone, tocolytics alone or no treatment.
 
 


699
Mauro Busacca, M.D., Francesco Maria Fusi, M.D., Claudio Brigante, M.D., Viviana Bonzi, D.Sc., Cristina Gonfiantini, M.D., Mario Vignali, M.D., and Augusto Ferrari, M.D.
In selected patients, growth hormone-releasing factor used with follicle stimulating hormone to induce follicular development resulted in an increase in the number and size of follicles.
 
 


704
Todd S. Harwell, M.P.H., M.T.(ASCP), Michael R. Spence, M.D., M.P.H., Alicia Sands, M.P.H., and Martin Y. Iguchi, Ph.D.
Substance use histories and urine drug screening should be considered in patients seeking family family planning services.